BCTX · BriaCell Therapeutics Corp. · Financials
$3.63
+0.03 (+0.83%)
At close · Sep 11
Going-concern doubt
— flagged Jun 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, the Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to continue to obtain the necessary financing to meet its obligations arising from normal business operations when they come due. The uncertainty of the Company's ability to raise such financial capital casts substantial doubt on the Company's ability to continue as a going concern.”View the 10-Q filed Jun 9, 2026
Market Cap
$31.58M
Shares
8.70M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Diluted EPS
-$62.19
-42.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $25.81M | $21.27M | $27.18M | $15.34M | $8.02M | $2.02M | $2.43M | |
| — | $15.27K | $15.27K | $15.27K | $15.27K | $15.26K | — | |
| — | — | — | — | $15.27K | $15.26K | $15.26K | |
| $32.03M | $27.2M | $33.33M | $23.27M | — | — | — | |
| — | $36.98K | — | — | $979 | $78.55K | — | |
| $406.78K | $119.96K | $288.02K | $891.21K | $136.73K | $3149 | — | |
| $475.41K | $114.51K | $262.57K | $850.34K | -$11.55M | -$6.84M | — | |
| -$218.5K | -$224.21K | -$106.51K | — | — | — | — | |
| — | $26.56M | $4.93M | $20.3M | -$26.84M | -$13.82M | — | |
| — | — | — | — | $0 | — | — | |
| -$301.12K | -$244.27K | -$140.08K | — | — | — | — | |
| — | -$26.31M | -$4.79M | -$20.3M | -$26.84M | -$13.82M | — | |
| USD/shares | $2.29 | -$62.19 | -$43.68 | -$13.00 | -$17.30 | -$30.60 | — |
| USD/shares | $2.29 | -$62.19 | -$43.68 | -$13.00 | -$17.30 | — | — |
| shares | — | 423.11K | 109.7K | 1.56M | 1.55M | 451.96K | — |
| shares | — | 423.11K | 109.7K | 1.56M | 1.55M | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.86×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.40×
Peer medians compare against the 256 similar-size Biotechnology companies (of 516 listed).